Management of Neurogenic Bladder

Introduction to Treatment

The American Urological Association recommends clean intermittent catheterization (CIC) combined with anticholinergic medications as the first-line treatment for neurogenic bladder, as it preserves renal function, reduces urinary tract infections, and maintains social continence 1, 2

The European Association of Urology recommends intermittent catheterization over permanent catheters to facilitate bladder emptying in patients with neurogenic bladder, due to lower rates of urinary tract infections, bladder stones, and improved quality of life 1
The use of hydrophilic catheters is associated with fewer urinary tract infections and hematuria in patients with spinal cord injuries 3

The American Urological Association recommends anticholinergic medications, such as oxybutynin, for the treatment of neurogenic bladder, specifically for the relief of symptoms of detrusor overactivity 2
OnabotulinumtoxinA is recommended for patients with spinal cord injuries or multiple sclerosis who are refractory to oral medications, to improve bladder storage parameters, reduce incontinence episodes, and improve quality of life 1, 4

The American Urological Association recommends suprapubic catheterization over urethral catheterization for patients who require permanent catheterization, due to lower rates of urethral trauma, erosion, and destruction, and improved quality of life 1

The European Association of Urology recommends that antibiotic prophylaxis be reserved for high-risk situations, such as vesicoureteral reflux or hostile bladder, as the evidence shows that cranberry products, methenamine salts, and acidifying/alkalizing agents are not effective in preventing urinary tract infections in patients with neurogenic bladder 2, 3

The International Continence Society recommends that urodynamic studies be performed in the initial evaluation of patients with neurogenic bladder, even in the absence of symptoms, to identify elevated storage pressures that put the upper urinary tract at risk, and to guide treatment intensity 5, 6

The American Urological Association recommends annual follow-up, including focused physical examination, symptom evaluation, basic metabolic panel, and renal ultrasound to evaluate for hydronephrosis, in patients with neurogenic bladder 2, 5

The European Association of Urology recommends that continuous urinary drainage be considered for patients who are refractory to all conservative therapies, to prevent upper tract damage, and that surgical options, such as sphincterotomy or reconstruction of the lower urinary tract with intestinal segments, be considered in extreme cases 4, 5

OnabotulinumtoxinA injection is recommended for patients refractory to oral medications, improving bladder storage parameters, reducing incontinence episodes, and improving quality of life in patients with spinal cord injuries or multiple sclerosis, with the requirement for patients to be willing and able to perform self-catheterization if urinary retention develops post-injection 7, 8
Repeat injections of OnabotulinumtoxinA are necessary as effects diminish over time, highlighting the need for ongoing management in patients with refractory neurogenic bladder 7, 8
Posterior tibial nerve stimulation (PTNS) may be offered to carefully selected patients who continue to void spontaneously and have primarily storage symptoms, requiring 30 minutes of stimulation once weekly for 12 weeks, with ongoing maintenance treatments 7, 8

Indwelling urethral catheters should only be considered as an absolute last resort, such as when urinary incontinence has caused progressive decubiti, due to high risks of catheter-associated UTIs, urethral destruction, and urolithiasis 7, 8
Management with absorbent garments is always preferred to indwelling catheterization due to high risks of catheter-associated UTIs, urethral destruction, and urolithiasis 7, 8

Urinary diversion, including continent urinary diversion or conduit diversion, may be considered in extreme cases where all conservative therapies fail, carrying substantial risks including need for long-term catheterization and risk of malignancy 7, 8